A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
10/2002
10/31/2002	US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002	US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002	US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002	US20020161010 Treatment of various disorders associated with enhanced activity of kinase p38-alpha and/or transforming growth factor beta; antiinflammatory agents
10/31/2002	US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002	US20020161004 Antiinflammation agents
10/31/2002	US20020160992 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
10/31/2002	US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002	US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002	US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002	US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002	US20020160940 Modulation of endogenous gene expression in cells
10/31/2002	US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002	US20020160063 Legume products
10/31/2002	US20020160061 Use of legume products for the treatment of external aggressions
10/31/2002	US20020160053 Solution for promoting growth of tissue cells at wound sites and production process therefor
10/31/2002	US20020160027 Conjugate, its preparation and use
10/31/2002	US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002	US20020160010 Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
10/31/2002	US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002	DE10121092A1 Kosmetische oder dermatologische Formulierungen mit einem Gehalt an Sericosid und/oder Pflanzenextrakten, dasselbe enthaltend Cosmetic or dermatological formulations with a content of sericoside and / or plant extracts containing the same
10/31/2002	DE10120315A1 Verwendung von Klee-Extrakt in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe gegen und Behandlung von degenerativen Hauterscheinungen Use of clover extract in cosmetic or dermatological preparations for the prophylaxis and treatment of degenerative skin symptoms
10/31/2002	CA2681952A1 Drug delivery matrices to enhance wound healing
10/31/2002	CA2483507A1 Enzyme and snp marker for disease
10/31/2002	CA2445740A1 Use of metals to treat inflammatory skin conditions
10/31/2002	CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue
10/31/2002	CA2445729A1 Use of metals to treat mucosal membranes
10/31/2002	CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002	CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002	CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002	CA2444675A1 Secreted proteins
10/31/2002	CA2444595A1 Benzimidazolone derivatives
10/31/2002	CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002	CA2443939A1 Dermatological composition comprising nicotinic acid or an amide, and a sphingoid base
10/31/2002	CA2443935A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002	CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/31/2002	CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	CA2436273A1 Method for producing an active ingredient concentrate, and an active ingredient concentrate
10/30/2002	EP1252894A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
10/30/2002	EP1252888A1 Biologically active labdane or labdene derivatives from Cistus
10/30/2002	EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002	EP1252882A1 Process to increase the threshold tolerance of the sensitive skin
10/30/2002	EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002	EP1252306A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
10/30/2002	EP1252177A1 Ligand for vascular endothelial growth factor receptor
10/30/2002	EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002	EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002	EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002	EP1252154A1 Heterocyclic amide derivatives
10/30/2002	EP1252153A1 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
10/30/2002	EP1252150A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
10/30/2002	EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002	EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002	EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
10/30/2002	EP1251852A1 Use of desloratadine for treating allergic and inflammatory conditions
10/30/2002	EP1251848A1 Gyrase inhibitors and uses thereof
10/30/2002	EP1251818A1 Galenic formulation
10/30/2002	EP1152731A4 A skin care composition that mediates cell to cell communication
10/30/2002	EP0726911B1 Treatment of hematologic disorders with a igf-1/igfbp-3 complex
10/30/2002	CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002	CN1377408A The PRV-1 gene and use thereof
10/30/2002	CN1377405A Personal care articles
10/30/2002	CN1377352A Selective antagonists of A28 adenosine receptors
10/30/2002	CN1377348A 4,5-diaryloxazole compounds with prostaglandin 12 (PG12) agonistic activity
10/30/2002	CN1377346A Z-pyrazoline-5-ones
10/30/2002	CN1377279A Use of soluble cosmetimulatory molecules to enhance immune responses
10/30/2002	CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002	CN1377277A Use of leptin in inhibition of endothelial cell proliferation
10/30/2002	CN1377274A Treatment of chronic viral infections with i (M. Vannae)
10/30/2002	CN1377268A Cell adhesion inhibitors
10/30/2002	CN1377259A ACE-2 inhibiting compounds and methods of use thereof
10/30/2002	CN1377257A Hybrid matrices and hybrid matrix mixtures
10/30/2002	CN1376664A Propynyl or diene diaryl compounds
10/30/2002	CN1376508A Capsule for treating cholasma and acne and its preparing process
10/30/2002	CN1376505A Composite medicine for moistening intestine, relaxing bowels and nourishing skin
10/30/2002	CN1376492A Medicine for treating recurrent aphtha and eczema
10/30/2002	CN1376487A Detoxicating and skin-growing ointment for treating burn
10/30/2002	CN1376486A Detoxicating and skin-growing powder for treating burn
10/30/2002	CN1376473A Chinese medicine for treating burn and scald
10/30/2002	CN1376465A Method and apparatus for releasing L-ascorbic acid to derma cortex
10/30/2002	CN1093417C Medicine for treating hair pore shrinkage and its praparing process
10/30/2002	CN1093408C Composition of radio sophorae flavescentis green tea and preparation thereof and its application in treating condyloma
10/30/2002	CN1093406C Wound healing oil and its preparation
10/30/2002	CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002	US6472432 Treatment of rosacea using lipoic acid
10/29/2002	US6472427 Enantiomers of 4-[[(cyanoimino) [(1,2,2-trimethylpropyl)amino]methyl]amino]benzonitrile
10/29/2002	US6472418 Non-peptide NK1 receptors antagonists
10/29/2002	US6472415 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
10/29/2002	US6472412 Compounds as PDE IV and TNF inhibitors
10/29/2002	US6472379 Angiogenesis inhibition
10/29/2002	US6472368 Compounds and methods for modulating adhesion molecule function
10/29/2002	US6472195 Human kallikrein
10/29/2002	US6472181 Hybrid matrix implants and explants
10/29/2002	US6471997 Antagonist of calcitonin gene related peptide, cgrp and/or of substance p; cosmetic
10/29/2002	US6471973 Drugs, cosmetics, dietetics, agriculture
10/29/2002	US6471954 Water-soluble glycerine and plant extracts, oil soluble emulsifiers, squalane and avocado oil are separately and inter mixed under pressure, further adding alpha-tocopherol, tocopherol acetate, retinyl palmitate and retinyl acetate;
10/29/2002	US6471949 Cosmetics; for artificially coloring the skin
10/29/2002	CA2283314C Ointment for the treatment of burns and of other skin diseases
10/24/2002	WO2002083950A1 Methods and compositions for treating cardiovascular disease using 10218

1 ... 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 ... 1065